Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.

[1]  S. Windecker,et al.  Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. , 2018, Journal of the American College of Cardiology.

[2]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[4]  J. Cho,et al.  Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. , 2017, JACC. Cardiovascular interventions.

[5]  S. Windecker,et al.  Rationale and design of the Hunting for the off‐target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI‐TECH) trial , 2017, American heart journal.

[6]  S. Mundell,et al.  Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. , 2016, Blood.

[7]  I. Xanthopoulou,et al.  Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation. , 2016, Current vascular pharmacology.

[8]  R. Schulz,et al.  Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. , 2014, Journal of the American College of Cardiology.

[9]  R. Guieu,et al.  Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. , 2014, Journal of the American College of Cardiology.

[10]  J. Sidaway,et al.  Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 , 2014, Journal of cardiovascular pharmacology and therapeutics.

[11]  J. Larsson,et al.  Ticagrelor Improves Peripheral Arterial Function in Patients with a Previous Acute Coronary Syndrome , 2013, Cardiology.

[12]  K. Nelander,et al.  Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism , 2012, Journal of thrombosis and haemostasis : JTH.

[13]  Amir Lerman,et al.  The Assessment of Endothelial Function: From Research Into Clinical Practice , 2012, Circulation.

[14]  G. Stouffer,et al.  Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers. , 2012, The American journal of cardiology.

[15]  M. Chow,et al.  Test–retest reliability of pulse amplitude tonometry measures of vascular endothelial function: Implications for clinical trial design , 2012, Vascular medicine.

[16]  R. Rubinshtein,et al.  Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. , 2010, European heart journal.

[17]  C. Cannon,et al.  Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel , 2010, Clinical cardiology.

[18]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[19]  C. Cannon,et al.  Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[20]  H. Makita,et al.  Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. , 1999, American journal of respiratory and critical care medicine.